Mr. Berman earned a BS degree in Industrial and Labor Relations and an MBA at Cornell University. He and his wife Judith, a professor of molecular genetics at the University of Minnesota, reside in Minneapolis and have two sons.
Mr. Berman has been involved with a number of trade and business associations including the American-Israel Chamber of Commerce, Memorial Blood Centers Business Advisory Group, and the University of Minnesota Institute of BioMedical Engineering.
In addition, he served as Chairman of the Minneapolis Jewish Community Foundation from 2002-2005, a board member of the Minneapolis Jewish Day School, a member of the American Heart Association Executive Leadership team in 2006-2007, and Corporate Chair of the Juvenile Diabetes Association 1997 Walkathon.
About Stenting and MGuard™ EPS™
Standard stents were not engineered for heart attack patients. They were designed for treating stable angina patients whose occlusion is different from that of an occlusion in a heart attack patient.
In acute heart attack patients, the plaque or thrombus is unstable and often breaks up as the stent is implanted causing downstream blockages (some of which can be fatal) in a significant portion of heart attack patients.
The MGuard[TM] EPS[TM] is integrated with a precisely engineered micro net mesh that prevents the unstable arterial plaque and thrombus (clots) that caused the heart attack blockage from breaking off.
While offering superior performance relative to standard stents in STEMI patients, the MGuard EPS requires no change in current physician practice - an important factor in promoting acc
|SOURCE Inspire MD|
Copyright©2012 PR Newswire.
All rights reserved